Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study
Veterinary and Comparative Oncology · 2023
DOI: 10.1111/vco.12873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Jae-Hyeon Im und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seo…. Hauptthemen laut MEDLINE: Dog Diseases, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Seoul National University, BK21 PLUS Program.
Abstract (Originalsprache)
Interleukin 2 receptor (IL‐2R) is released from activated T cell lymphocytes and related to proliferation of B cells and T cells. Beta‐2‐microglobulin (B2M) is synthesized from all nucleated cells and constitutes a major histocompatibility complex class I antigen. In human medicine, high concentrations of these two factors have been found to be related to prognosis in aggressive non‐Hodgkin's lymphoma. In this pilot study, we aimed to assess the correlation between the serum concentration of IL‐2R and B2M and the diagnosis and prognosis of canine lymphoma. This study included 8 healthy dogs and 17 dogs with lymphoma. To measure the serum concentration of IL‐2R and B2M, a commercial enzyme‐linked immunosorbent assay was used. In dogs with lymphoma, IL‐2R concentrations were significantly high at the time of diagnosis, but B2M concentrations were not. In relapsed dogs, both IL‐2R and B2M concentrations were significantly higher than those in the control and chemotherapy response groups. When the serum concentrations of IL‐2R and B2M during chemotherapy were monitored in four relapsed dogs, B2M levels were more closely related with relapse. This study demonstrated that serum IL‐2R and B2M concentration can be a diagnostic or prognostic tool for canine lymphoma. Monitoring of serum B2M concentration seems to be useful for predicting relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
- Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
- Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea.
ORCID-Profile: Kyoung-Won Seo, Hwa-Young Youn
Förderung
- Seoul National University
- BK21 PLUS Program
Zitieren
APA
Im, J. H., Park, S. M., An, J. H., Kim, T. H., Chae, H. K., Oh, Y. I., Seo, K. W., & Youn, H. Y. (2023). Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12873
Vancouver
Im JH, Park SM, An JH, Kim TH, Chae HK, Oh YI, et al. Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12873
BibTeX
@article{Im2023,
author = {Im, Jae-Hyeon and Park, Su-Min and An, Ju-Hyun and Kim, Tea-Hee and Chae, Hyung-Kyu and Oh, Ye-In and Seo, Kyoung-Won and Youn, Hwa-Young},
title = {Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study},
journal = {Veterinary and Comparative Oncology},
year = {2023},
doi = {10.1111/vco.12873}
}
EUVIMED